Enanta Pharmaceuticals Inc


Prices are adjusted according to historical splits.

Enanta Pharmaceuticals Inc Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$539.23 million
Book Value:
Revenue TTM:
$81.18 million
Operating Margin TTM:
Gross Profit TTM:
$86.16 million
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

Enanta Pharmaceuticals Inc had its IPO on 2013-03-21 under the ticker symbol ENTA.

The company operates in the Healthcare sector and Biotechnology industry. Enanta Pharmaceuticals Inc has a staff strength of 160 employees.

Stock update

Shares of Enanta Pharmaceuticals Inc opened at $12.52 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $12.52 - $13.29, and closed at $13.07.

This is a +4.81% increase from the previous day's closing price.

A total volume of 544,654 shares were traded at the close of the day’s session.

In the last one week, shares of Enanta Pharmaceuticals Inc have slipped by -11.33%.

Enanta Pharmaceuticals Inc's Key Ratios

Enanta Pharmaceuticals Inc has a market cap of $539.23 million, indicating a price to book ratio of 2.8795 and a price to sales ratio of 10.5822.

In the last 12-months Enanta Pharmaceuticals Inc’s revenue was $81.18 million with a gross profit of $86.16 million and an EBITDA of $-126630000. The EBITDA ratio measures Enanta Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Enanta Pharmaceuticals Inc’s operating margin was -158.98% while its return on assets stood at -22% with a return of equity of -39.71%.

In Q1, Enanta Pharmaceuticals Inc’s quarterly earnings growth was a negative -66.2% while revenue growth was a negative 4.9%.

Enanta Pharmaceuticals Inc’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $-6.53 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Enanta Pharmaceuticals Inc’s profitability.

Enanta Pharmaceuticals Inc stock is trading at a EV to sales ratio of 8.1396 and a EV to EBITDA ratio of -5.8021. Its price to sales ratio in the trailing 12-months stood at 10.5822.

Enanta Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$326.45 million
Total Liabilities
$32.17 million
Operating Cash Flow
$46.77 million
Capital Expenditure
$2.38 million
Dividend Payout Ratio

Enanta Pharmaceuticals Inc ended 2023 with $326.45 million in total assets and $0 in total liabilities. Its intangible assets were valued at $326.45 million while shareholder equity stood at $269.38 million.

Enanta Pharmaceuticals Inc ended 2023 with $0 in deferred long-term liabilities, $32.17 million in other current liabilities, 210000.00 in common stock, $-139823000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $73.18 million and cash and short-term investments were $210.08 million. The company’s total short-term debt was $4,923,000 while long-term debt stood at $0.

Enanta Pharmaceuticals Inc’s total current assets stands at $271.14 million while long-term investments were $15.04 million and short-term investments were $136.91 million. Its net receivables were $46.57 million compared to accounts payable of $11.76 million and inventory worth $0.

In 2023, Enanta Pharmaceuticals Inc's operating cash flow was $46.77 million while its capital expenditure stood at $2.38 million.

Comparatively, Enanta Pharmaceuticals Inc paid $0 in dividends in 2023.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

Enanta Pharmaceuticals Inc stock is currently trading at $13.07 per share. It touched a 52-week high of $76.36 and a 52-week low of $76.36. Analysts tracking the stock have a 12-month average target price of $42.13.

Its 50-day moving average was $17.13 and 200-day moving average was $33.97 The short ratio stood at 3.15 indicating a short percent outstanding of 0%.

Around 659.4% of the company’s stock are held by insiders while 9365.7% are held by institutions.

Frequently Asked Questions About Enanta Pharmaceuticals Inc

The stock symbol (also called stock or share ticker) of Enanta Pharmaceuticals Inc is ENTA

The IPO of Enanta Pharmaceuticals Inc took place on 2013-03-21

Similar Industry Stocks (Biotechnology)

Last Price
Jindal Saw Limited (JINDALSAW)
MaxCyte Inc (MXCT)

Most Active

Last Price
Amyris Inc (AMRS)
Humbl Inc (HMBL)

Top Gainers

Last Price
Latch Inc (LTCHW)

Top Losers

Last Price


Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.


500 Arsenal Street, Watertown, MA, United States, 02472